Man Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.1M | Buy |
367,981
+58,322
| +19% | +$3.19M | 0.03% | 488 |
|
|
2026
Q1 | $17.5M | Sell |
309,659
-51,836
| -14% | -$3.02M | 0.03% | 558 |
|
|
2025
Q4 | $21.5M | Sell |
361,495
-1,131,884
| -76% | -$61.6M | 0.04% | 489 |
|
|
2025
Q3 | $80.9M | Buy |
1,493,379
+16,457
| +1% | +$941K | 0.14% | 161 |
|
|
2025
Q2 | $81.2M | Buy |
1,476,922
+672,628
| +84% | +$39.6M | 0.15% | 143 |
|
|
2025
Q1 | $56.9M | Buy |
804,294
+301,659
| +60% | +$20.3M | 0.14% | 163 |
|
|
2024
Q4 | $33M | Sell |
502,635
-113,443
| -18% | -$7.6M | 0.09% | 269 |
|
|
2024
Q3 | $43.3M | Buy |
616,078
+485,670
| +372% | +$40.6M | 0.11% | 229 |
|
|
2024
Q2 | $10.7M | Buy |
130,408
+45,362
| +53% | +$3.78M | 0.03% | 678 |
|
|
2024
Q1 | $7.43M | Buy |
85,046
+20,703
| +32% | +$1.85M | 0.02% | 824 |
|
|
2023
Q4 | $6.2M | Buy |
+64,343
| New | +$5.69M | 0.02% | 858 |
|
|
2023
Q3 | – | Sell |
-279,334
| Closed | -$24.9M | – | 698 |
|
|
2023
Q2 | $24.2M | Buy |
+279,334
| New | +$26.3M | 0.07% | 329 |
|
|
2023
Q1 | – | Sell |
-663,969
| Closed | -$68.8M | – | 81 |
|
|
2022
Q4 | $68.7M | Buy |
663,969
+115,421
| +21% | +$10.8M | 0.25% | 88 |
|
|
2022
Q3 | $46.5M | Buy |
+548,548
| New | +$48.8M | 0.22% | 110 |
|
|
2022
Q2 | – | Sell |
-64,777
| Closed | -$5.16M | – | 407 |
|
|
2022
Q1 | $5M | Buy |
+64,777
| New | +$5.42M | 0.02% | 898 |
|
|
2021
Q4 | – | Sell |
-10,764
| Closed | -$832K | – | 1959 |
|
|
2021
Q3 | $832K | Sell |
10,764
-5,515
| -34% | -$435K | ﹤0.01% | 1388 |
|
|
2021
Q2 | $1.36M | Sell |
16,279
-47,504
| -74% | -$3.77M | ﹤0.01% | 1320 |
|
|
2021
Q1 | $4.82M | Buy |
63,783
+17,868
| +39% | +$1.46M | 0.02% | 707 |
|
|
2020
Q4 | $4.03M | Buy |
45,915
+656
| +1% | +$52K | 0.02% | 921 |
|
|
2020
Q3 | $3.44M | Sell |
45,259
-48,177
| -52% | -$4.87M | 0.01% | 992 |
|
|
2020
Q2 | $11.5M | Buy |
93,436
+64,813
| +226% | +$6.44M | 0.06% | 317 |
|
|
2020
Q1 | $2.42M | Sell |
28,623
-13,677
| -32% | -$1.18M | 0.02% | 811 |
|
|
2019
Q4 | $3.58M | Buy |
42,300
+3,460
| +9% | +$261K | 0.01% | 1118 |
|
|
2019
Q3 | $2.62M | Buy |
38,840
+1,522
| +4% | +$117K | 0.01% | 1156 |
|
|
2019
Q2 | $3.2M | Sell |
37,318
-6,037
| -14% | -$516K | 0.01% | 1137 |
|
|
2019
Q1 | $3.85M | Sell |
43,355
-31,711
| -42% | -$2.94M | 0.01% | 1049 |
|
|
2018
Q4 | $6.39M | Sell |
75,066
-14,116
| -16% | -$1.34M | 0.03% | 641 |
|
|
2018
Q3 | $8.65M | Buy |
89,182
+63,109
| +242% | +$6.3M | 0.03% | 702 |
|
|
2018
Q2 | $2.46M | Sell |
26,073
-91,113
| -78% | -$7.98M | 0.01% | 1277 |
|
|
2018
Q1 | $9.5M | Buy |
+117,186
| New | +$10.1M | 0.04% | 521 |
|
Other funds holding BMRN
VPC
Man Group's BMRN Position: Q2 2026 in Review
Man Group increased its BioMarin Pharmaceuticals (BMRN) stake by 19% in Q2 2026, buying an estimated $3.19M and bringing the position to 367,981 shares worth $21.1M. The position accounts for 0.03% of the portfolio, ranked #488.
Man Group first reported a position in BMRN in Q1 2018 and has held it in 30 quarters since. The position peaked at $81.2M in Q2 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Man Group held 367,981 shares of BioMarin Pharmaceuticals worth $21.1M as of Q2 2026.
- Man Group bought 58,322 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.19M.
- BioMarin Pharmaceuticals made up 0.03% of Man Group's portfolio in Q2 2026, its #488 holding.
- Man Group first reported a position in BioMarin Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
- Man Group's BioMarin Pharmaceuticals position peaked at $81.2M in Q2 2025.
- 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.